Compare HTCR & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HTCR | GOVX |
|---|---|---|
| Founded | 2009 | 2001 |
| Country | Japan | United States |
| Employees | N/A | 17 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4M | 4.0M |
| IPO Year | 2022 | N/A |
| Metric | HTCR | GOVX |
|---|---|---|
| Price | $3.07 | $1.18 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 94.5K | ★ 3.5M |
| Earning Date | 05-14-2026 | 04-15-2026 |
| Dividend Yield | ★ 87.84% | N/A |
| EPS Growth | ★ 414.29 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,407,229.00 | N/A |
| Revenue This Year | $123.26 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 39.19 | N/A |
| 52 Week Low | $0.15 | $0.12 |
| 52 Week High | $3.97 | $4.40 |
| Indicator | HTCR | GOVX |
|---|---|---|
| Relative Strength Index (RSI) | 48.47 | 38.86 |
| Support Level | $2.80 | $1.15 |
| Resistance Level | $3.86 | $2.00 |
| Average True Range (ATR) | 0.39 | 0.24 |
| MACD | -0.04 | -0.12 |
| Stochastic Oscillator | 11.34 | 5.08 |
HeartCore Enterprises Inc is a software development company providing solutions for digital transformation (DX). It develops, sells, and maintains CMS and CXM platforms using digital marketing technology, RPA, process mining solutions, myInvenio and Apromore, task mining solution CONTROLIO, and 3D-VR services including Matterport and VR360. The company also provides management consulting, education, services, and support to help customers succeed with the CXM Platform. It operates through two business units, the CX division for customer experience management and the DX division for digital transformation, which provides robotics process automation, process mining, and task mining. Its products include VR360, myInvenio, Apromore, and others, with maximum revenue from the United States.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.